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Résumé en
anglais
Helper-dependent adenoviral (HDAd) vectors are attractive for liver-directed gene
therapy because they can drive sustained high levels of transgene expression
without chronic toxicity. However, high vector doses are required to achieve
efficient hepatic transduction by systemic delivery because of a nonlinear dose
response. Unfortunately, such high doses result in systemic vector dissemination
and dose-dependent acute toxicity with potential lethal consequences. We have
previously shown in nonhuman primates that delivery of HDAd in surgically isolated
livers resulted in a significantly higher hepatic transduction with reduced systemic
vector dissemination compared with intravenous delivery and multiyear transgene
expression. Encouraged by these data, we have now employed a surgical vector
delivery method in the Gunn rat, an animal model for Crigler-Najjar syndrome. After
vector delivery into the surgically isolated liver, we show phenotypic correction at
the low and clinically relevant vector dose of 1 × 10(11) vp/kg. Correction of
hyperbilirubinemia and increased glucuronidation of bilirubin in bile was achieved
for up to 1 year after vector administration. Surgical delivery of the vector was well
tolerated without signs of acute or chronic toxicity. This method of delivery could
thereby be a safer alternative to liver transplantation for long-term treatment of
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